Biostate AI is a biotechnology company that leverages artificial intelligence to drastically reduce the cost and time of RNA sequencing. By combining nanotechnology with machine learning, the platform allows researchers to perform multi-omics analysis with unprecedented precision. This technology is critical for the development of personalized medicine and the acceleration of clinical trials. Based in Palo Alto and backed by a 2025 Series A round from Accel, Biostate is positioning itself as the core data engine for the next generation of biotech breakthroughs.
